INTRODUCTION
Immune dysregulation is the cause of human autoimmune disorders. Multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS), results from uncontrolled autoreactive T cells that infiltrate the CNS and attack the myelin sheath (1, 2) . In particular, T helper 17 (T H 17) cells, a subset of CD4 + effector T cells that secrete the proinflammatory cytokine interleukin-17 (IL-17), play a key pathogenic role in MS (3) . In experimental autoimmune encephalomyelitis (EAE), the principal animal model used to study the neuroinflammatory events associated with MS (4), autoimmune inflammation occurs in a multistep process, which includes both the induction and effector phases. Myelin-reactive CD4 + T cells are activated in the periphery and then enter the perivascular space of the CNS, in which they reencounter myelin antigens presented by local antigen-presenting cells (APCs). After reactivation, these T cells invade the CNS parenchyma, recognize antigens on myelinated axons, and release IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), and other proinflammatory molecules, which in turn stimulate CNS-resident cells to activate an inflammatory cascade. Therefore, a complex inflammatory reaction involving both the adaptive and innate immune systems governs disease progression.
The differentiation of T H 17 cells is orchestrated by polarizing cytokines, including IL-1, IL-6, transforming growth factor-b (TGF-b), and IL-23, which are mainly produced by APCs, especially dendritic cells (DCs) (3) . Studies have revealed an intricate network of molecular pathways that program the differentiation of T H 17 cells. At the transcriptional level, T H 17 cell differentiation requires the function of a set of transcription factors, including RAR-related orphan receptor a (RORa), RORgt, interferon (IFN) regulatory factor 4 (IRF4), signal transducer and activator of transcription 3 (STAT3), and runt-related transcription factor 1 (RUNX1) (3) . In contrast to our extensive knowledge of the T cell-intrinsic pathways that are required for IL-17 production, there has been far less emphasis on how T H 17 cells mediate the inflammation of target tissues at the molecular level. Available evidence suggests that both IL-17 and GM-CSF produced by T H 17 cells contribute to the encephalitogenic program (5) (6) (7) (8) . IL-17 and IL-17 receptors (IL-17Rs) are the founding members of a particular subclass of cytokines and receptors that exhibit signaling properties distinct from those of the better-defined cytokines and their receptors, such as the tumor necrosis factor receptor (TNFR), IL-1R, and IL-12R families (9) . Although studies have identified the pathogenic roles of IL-17Rs (10) and the IL-17R signaling adaptor molecule Act1 (11, 12) , how T H 17 cells participate in EAE pathogenesis and, in particular, how IL-17R signals are transduced by an intracellular signaling network in target cells remain unresolved.
Mitogen-activated protein kinases (MAPKs), which include extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, constitute fundamental pathways for cellular responses to a wide range of inflammatory signals (13) . In particular, p38 MAPK is, by far, the most extensively investigated protein kinase target for the development of anti-inflammatory drugs in the pharmaceutical industry because of its potent role in inflammation and the availability of a large array of pharmacological inhibitors (14) ; however, the nonspecific effects inherent in pharmacological approaches make them unlikely to provide definitive mechanistic insights (15, 16) . Notably, p38 inhibitors interfere with the functions of important immune regulators, such as receptor-interacting protein 2 (RIP2) (17) and the Akt-mechanistic target of rapamycin (mTOR) pathway (18) . From this perspective, genetic dissection of signaling pathways has been highly instrumental in our understanding of the specific roles of MAPKs in immune cells (13, 19) . For example, we and others established a key role for p38a in DCs in mediating the crosstalk between innate and adaptive immunity for the induction of T H 17 cell differentiation, as well as for the pathogenesis of autoimmune disorders (20, 21) . Conversely, MAPK phosphatase 1 (MKP-1), a potent inhibitor of p38 and other MAPKs (22) , suppresses the DC-dependent differentiation of T H 17 cells (23) . Moreover, p38a exerts both pro-and anti-inflammatory activities in a cell contextdependent manner (24, 25) . These effects contribute to the variable effects observed in the preclinical and clinical targeting of p38a, and reinforce the importance of genetic dissection of p38a functions in vivo.
Despite these advances in our understanding of the physiological roles of p38a in immune cells, little evidence exists about the functional importance of p38a in tissue-resident cells for mediating autoimmune inflammation. Another open question is the specific stages regulated by p38a in disease pathogenesis. Here, we report the time-and tissue-specific effects of p38a signaling in CNS-resident cells in mediating T H 17 cell-dependent inflammation of the CNS. Temporally, p38a played an important role in the effector phase of EAE; anatomically, p38a acted in CNS-resident cells, especially astrocytes, in propagating a T H 17 cell-mediated inflammatory cascade. These effects were associated with the role of p38a in promoting the production of the chemokines required for the recruitment of peripheral inflammatory cells that infiltrated the CNS and promoted inflammation. Furthermore, we found that loss of p38a in astrocytes and mouse embryonic fibroblasts (MEFs) diminished IL-17-induced proinflammatory gene expression, which was associated with the defective activation of MAPK-activated protein kinase 2 (MK2), a downstream target of p38a. Finally, we found that MKP-1 functioned in a reciprocal manner to p38a in regulating CNS pathogenesis as well as IL-17 and IL-17R signaling; however, a closely related MAPK, JNK, was dispensable for IL-17R signaling. Collectively, our studies identify a key mechanism of CNS inflammation mediated by the p38a-MKP-1 axis that links IL-17 and IL-17R signaling to the expression of genes encoding proinflammatory factors in CNS-resident cells.
RESULTS
p38a is required for the effector phase of EAE The p38 MAPK pathway is an important regulator and therapeutic target of inflammation (13, 14) . Microarray analysis has identified the increased expression of the gene encoding p38a in MS lesions in the CNS (26) . To investigate the role of p38 in the murine model of neuroinflammation, we immunized wild-type mice with myelin oligodendrocyte glycoprotein (MOG) peptide and complete Freund's adjuvant (CFA), and then injected them with pertussis toxin to induce EAE. We found that both the abundance and phosphorylation of p38a were markedly increased in spinal cord cells of mice with active EAE compared to those in the spinal cord cells of mice without immune challenge (Fig. 1A) CreER mice (20) . After immunization of wild-type and p38a
CreER mice with MOG peptide and CFA, we started treating them with tamoxifen at the onset of clinical disease (at day 12 or 13 after immunization), which corresponded to the initiation of the effector phase of EAE, and continued treatment for a total of 3 days. Treatment with tamoxifen resulted in a substantial reduction in p38 abundance and activity in the spinal cords and brains of p38a
CreER mice ( fig. S1 ), indicating a predominant contribution of p38a, but not other p38 family members, to the total activity of p38 in inflammation of the CNS. In contrast, the activities of other signaling pathways, including those mediated by ERK, JNK, and nuclear factor kB (NF-kB), were largely comparable between tamoxifen-treated wild-type and p38a
CreER mice, except for a slight reduction in the abundance of phosphorylated ERK in the spinal cords of the p38a
CreER mice ( fig. S1 ). In this treatment regimen, tamoxifen markedly delayed disease progression in the p38a
CreER mice and ameliorated clinical scores (Fig. 1B) . Furthermore, treatment of p38a
CreER mice with tamoxifen during EAE disease remission (days 21 to 23 after immunization) resulted in a modestly reduced disease score ( fig. S2A ). These results are suggestive of an important role for p38a in the effector phase of CNS inflammation.
Despite the heterogeneity of immune responses in EAE, T H 17 cells are crucial for disease pathogenesis (3). Consistent with this notion, neutralization of IL-17 signaling with an anti-IL-17 antibody substantially ameliorated EAE pathogenesis in wild-type mice, although the effect was less profound than that caused by the loss of p38a ( fig. S2B ). Furthermore, neutralization of IL-17 reduced the phenotypic difference in EAE between wild-type and p38a-deficient mice ( fig. S2B ). To further investigate the direct contribution of p38a to the effector phase of CNS inflammation, we used a transfer model of EAE by injecting T H 17-polarized cells into recipient mice (20, 27) . Briefly, we isolated draining lymph node (DLN) cells from MOG-immunized wild-type mice, cultured them with MOG and IL-23 in vitro, and transferred the resulting cells into tamoxifen-treated wild-type and p38a
CreER mice. Whereas wild-type mice rapidly developed EAE, the p38a-deficient mice exhibited delayed disease development (Fig. 1C) . Histological analysis of spinal cords revealed that, compared to the wild-type recipient mice, the p38a
CreER recipient mice had decreased inflammation and demyelination, as revealed by staining with hematoxylin and eosin (H&E) and Luxol fast blue (a copper phthalocyanine dye that stains the myelin sheath), respectively ( Fig. 1, D and E). Immunostaining further showed that there were reduced numbers of CD3 + T cellls and Iba1 + macrophages and microglia in p38a CreER mice (Fig. 1D) . Results from these complementary systems suggest an important role for p38a in the effector phase of EAE.
p38a function in CNS-resident cells is required for EAE
We next determined the cell type-specific requirement for p38a in mediating the inflammatory responses in the CNS by focusing on nonimmune cells in the target tissue. To this end, we crossed p38a fl/fl mice with NestinCre mice (to generate "p38a
NesCre mice"); the Nestin-Cre transgene mediates efficient gene inactivation in neuroectoderm-derived CNS-resident cells, namely, neurons, astrocytes, and oligodendrocytes (28, 29) . The gene encoding p38a was efficiently deleted in the brain and spinal cord, but not in the spleen or lymph nodes, of p38a
NesCre mice ( fig. S3 ). After immunization with MOG and CFA, p38a
NesCre mice exhibited delayed onset and diminished severity of EAE compared to wild-type mice ( Fig. 2A) . The immunized p38a
NesCre mice also exhibited decreased CNS inflammation and demyelination compared to the immunized wild-type mice, and showed less infiltration of T cells, macrophages, and microglia (Fig. 2 , B to D). We next used flow cytometry to examine the immune cells that had infiltrated the spinal cords of wild-type and p38a
NesCre mice at the peak stage of EAE. The p38a
NesCre mice had fewer numbers of total leukocytes (CD45 + ), and both the percentages and numbers of infiltrating macrophages (F4/80 + CD11b hi cells), CD4 + T cells, and CD8 + T cells were all substantially reduced compared to those in wild-type mice (Fig. 2 , E and F). These data suggest that p38a acts in CNS-resident cells to promote EAE and infiltration of the CNS by immune cells.
p38a promotes the production of chemokines and cytokines, but not the generation of T H 17 or T H 1 cells
Chemokines play an essential role in guiding the infiltration of inflammatory cells into tissues. To determine whether the CNS-restricted loss of p38a affected chemokine production, we measured the abundances of mRNAs of several chemokines that have been linked to EAE. Multiple mRNAs, including Ccl5, Cxcl2, and, to a lesser extent, Cxcl1 mRNA, were decreased in abundance in the CNS of p38a
NesCre mice compared to those in the CNS of wild-type mice (Fig. 3A) . We also examined the expression of genes encoding cytokines and matrix metalloproteinases that are involved in EAE pathogenesis. The abundances of Il6 and Mmp3 mRNAs, but not Mmp9 mRNA, were reduced in p38a
NesCre mice compared to those in wild-type mice (Fig. 3A) . These data suggest that p38a activity in CNS-resident cells mediates chemokine gene expression, which likely facilitates the infiltration of inflammatory cells into the CNS during EAE.
The efficient activation of autoreactive T cells is a prerequisite for the induction of CNS inflammation and pathology in EAE. Because we used CNS-specific ablation of p38a in our studies, peripheral immune functions should not be affected in these mice. To directly address this point, we examined the generation of T H 17 and T H 1 cells in MOG-immunized wild-type and p38a
NesCre mice. CD4 + T cells from the spleens and DLNs of p38a
NesCre mice had normal amounts of IL-17 and IFN-g (Fig. 3 , B and C). Furthermore, T cells from the immunized wild-type and p38a NesCre mice produced comparable amounts of Il17 and Ifng mRNAs upon ex vivo stimulation with MOG peptide ( fig. S4 ). Moreover, wild-type and p38a
NesCre mice contained similar percentages of IL-17-and IFN-gexpressing cells among CD4 + T cells in the spinal cord, although the total numbers of CD4 + T cells were decreased in the p38a NesCre mice (Fig. 3D ). These results suggest that the ameliorated EAE in p38a
NesCre mice was not caused by impaired differentiation of T H 17 or T H 1 cells.
Infiltration of the CNS with T H 17 cells is attenuated in p38a
NesCre mice
The requirement of p38a for increased chemokine mRNA abundance and T cell infiltration in the CNS, but not for T H 17 or T H 1 cell differentiation, prompted us to explore the role of p38a in the recruitment of MOGspecific T cells into CNS. MOG-specific T cells were isolated from DLN cells of CD45. (Fig. 3E) , there was less infiltration of donor CD4 + T cells into the CNS of p38a NesCre mice at 11 days after adoptive transfer compared to that of the CNS of wild-type recipients (Fig. 3F) . In addition, host-derived CD11b + myeloid cells were markedly reduced in numbers in the spinal cords of p38a
NesCre mice compared to those in the spinal cords of wild-type mice (Fig. 3G) , consistent with the role of IL-17 production in the CNS in mediating the subsequent recruitment of myeloid cells (3) . Furthermore, the amounts of Il6 and Mmp3 mRNAs were substantially reduced in the spinal cord cells of p38a NesCre recipient mice compared to those of wild-type recipients ( fig. S5C) . A similar trend was observed for Cxcl1 and Cxcl2 mRNAs, but this did not reach statistical significance in the limited number of mice analyzed ( fig. S5C ). Despite the considerable reduction in the number of donor CD4 + T cells in the CNS of p38a NesCre mice, those that infiltrated the tissue had comparable amounts of IL-17 and IFN-g to those of cells that infiltrated the CNS of wild-type mice (Fig. 3H) . Therefore, consistent with the requirement for p38a for chemokine expression in the CNS (Fig. 3A) p38a mediates IL-17-induced proinflammatory gene expression and MK2 activation IL-17, the signature cytokine for T H 17 cells, stimulates inflammation in autoimmune diseases (9, 30, 31) . We hypothesized that p38a mediated IL-17 signaling to induce expression of genes encoding inflammatory factors. To test this, we isolated MEFs from wild-type and p38a CreER mice, treated the cells with 4-hydroxytamoxifen (4-OHT), and stimulated them with IL-17, TNF-a, or both. The amount of CXCL1 protein in the culture medium of IL-17-treated p38a
CreER MEFs was substantially decreased compared to that in the culture medium of IL-17-treated wild-type cells (Fig. 4A) . To a lesser extent, p38a deficiency also resulted in a reduction in the amount of CXCL1 produced in response to TNF-a, as well as in response to both IL-17 and TNF-a. These results suggest that p38a is required for IL-17R signaling in MEFs. Results from a previous study highlighted the importance of IL-17R signaling in astrocytes for EAE (12) . To determine the role of p38a in astrocytes, we isolated astrocytes from wild-type and p38a
CreER mice and treated them with 4-OHT to deplete p38a in vitro, thereby circumventing any potential secondary effects that might occur as a result of the chronic loss of p38a in vivo. Depletion of p38a did not affect the relative expression of either of the genes encoding the IL-17R subunits IL-17RA and IL-17RC ( fig. S6A ), but it substantially reduced the expression of a number of IL-17-responsive genes in astrocytes. These include the chemokine-encoding genes Cxcl1, Cxcl2, Cxcl5, Ccl2, Ccl5, and Ccl7, as well as genes encoding other inflammatory factors, including Il6, Csf2, Lcn2, and Nfkbiz (Fig. 4B) . To determine the mechanisms underlying the p38a-mediated regulation of target gene expression, we examined the relative abundances of the primary transcripts of Cxcl1 and Cxcl2 and their decay rates in IL-17-stimulated astrocytes to measure transcription initiation frequency (32) and mRNA stability (33, 34) , respectively. We found that p38a deficiency mainly affected the expression of Cxcl1 and Cxcl2 rather than the stability of Cxcl1 and Cxcl2 mRNAs ( fig. S6, B and C) . Together, our findings from experiments with MEFs and astrocytes support a crucial role for p38a in mediating IL-17R signaling required for inflammatory gene expression.
We next examined signaling pathways activated by p38a in IL-17-stimulated astrocytes. Phosphorylation of MK2 and p38 was lost in p38a-deficient cells (Fig. 4C) . In contrast, phosphorylation of cyclic adenosine monophosphate response element-binding protein (CREB), another p38a target, was not affected by p38a deletion in IL-17-stimulated astrocytes. In addition, the activities of ERK and NF-kB were comparable between wild-type and p38a-deficient cells (Fig. 4C) . MK2 is implicated in T H 17 cell-dependent diseases such as arthritis (35) , although the physiological role of MK2 and its interaction with p38a in EAE are not defined. We hypothesized that an important pathway to transduce p38a signals in IL-17-stimulated astrocytes might be mediated by MK2. Indeed, treatment of astrocytes with an MK2 inhibitor reduced the expression of multiple inflammatory genes (Cxcl1, Cxcl2, Cxcl5, Ccl2, Ccl5, Ccl7, Il6, Csf2, Lcn2, and Nfkbiz) in response to IL-17 (Fig. 4D) . These data suggest that p38a links IL-17R signaling to the activation of MK2 to mediate proinflammatory gene expression.
MKP-1 activity in CNS-resident cells inhibits EAE pathogenesis and IL-17R signaling
Given the marked effects of p38a in CNS inflammation, it was critical to delineate the pathways that suppress its activity. MKP-1 is a potent inhibitor of the activities of p38 and other MAPKs (22, (36) (37) (38) . We therefore investigated the role of MKP-1 in CNS-resident cells in EAE. To exclude any potential roles of MKP-1 in DCs (23) or T cells (39) that might contribute to EAE, we generated bone marrow chimeric mice in which MKP-1 deficiency was restricted to the radio-resistant nonhematopoietic cell compartment, including CNS-resident cells, by transferring MKP-1 +/+ bone marrow cells into lethally irradiated MKP-1 +/+ and MKP-1 −/− recipient mice. Lack of MKP-1 in the radio-resistant cells rendered the mice more susceptible to EAE, which was associated with more severity and faster kinetics, as compared with the disease course in MKP-1 +/+ bone marrow chimeric mice (Fig. 5A) . Histological analysis revealed that there was more severe inflammation and increased infiltration of T cells as well as of macrophages or microglia in the spinal cords of MKP-1 −/− bone marrow chimeric mice at the peak of disease (Fig. 5, B and C) . Increased leukocyte infiltration was also observed in the cerebellum of MKP-1 −/− bone marrow chimeric mice ( fig. S7A ). These data suggest that lack of MKP-1 in radio-resistant cells exacerbates EAE.
To test the role of MKP-1 in IL-17 signaling, we stimulated wild-type and MKP-1 −/− MEFs with IL-17 alone or in combination with TNF-a.
Deficiency in MKP-1 is associated with enhanced p38 activity in MEFs (40) . MKP-1 −/− MEFs produced increased amounts of CXCL1 and IL-6 compared with wild-type MEFs (Fig. 5D) . JNK is another important target of MKP-1 (22) . However, inducible deletion of JNK did not alter the IL-17-stimulated expression of Cxcl1 or Il6 (fig. S7B ). These results suggest that the p38a-MKP-1 signaling axis, but not JNK signaling, regulates IL-17R signaling.
DISCUSSION
T H 17 cells function as a principal cell type in neuroinflammation, but the effector mechanisms mediating their pathogenicity in the CNS remain under debate. In addition to IL-17, T H 17 cells produce a number of other proinflammatory cytokines, including IL-17F, IL-21, IL-22, and GM-CSF (3). In particular, GM-CSF produced by T H 17 cells is a key stimulator of the encephalitogenic program (5, 6). Nonetheless, loss of IL-17, IL-17Rs, or Act1 or neutralization of IL-17 signaling substantially ameliorates EAE (7, 8, (10) (11) (12) , highlighting the important role of IL-17R signaling in inflammation of the CNS. Here, we showed that p38a mediates IL-17 signaling in CNS-resident cells, such as astrocytes, to stimulate the production of chemokines and proinflammatory factors, thereby sustaining neuroinflammation in the effector phase of EAE. In the absence of p38a signaling in CNS-resident cells, T H 17 cells failed to efficiently infiltrate into the CNS or recruit myeloid cells to propagate the inflammatory cascade; however, the generation of T H 17 cells per se was not affected. At the molecular level, we found that p38a linked IL-17R signaling to MK2 activation as an important mechanism for proinflammatory gene expression. Furthermore, we found that p38a and MKP-1 constituted a signaling axis to positively and negatively regulate IL-17R signaling and neuroinflammation, respectively, whereas the closely related kinase JNK was dispensable for IL-17R signaling. Together, these data suggest that the p38a-MKP-1 axis in CNS-resident cells orchestrates the effector phase of EAE by mediating the IL-17R-dependent activation of MK2 and the expression of genes that encode proinflammatory factors.
Among the target genes downstream of IL-17 signaling are those encoding a distinct subset of chemokines and cytokines that are implicated in the pathogenesis of EAE (12, 41) . Consistent with the reduced amounts of these proinflammatory factors in the CNS of p38a NesCre mice after induction of EAE, loss of p38a attenuated the expression of these genes in IL-17-stimulated astrocytes in vitro. This effect was likely mediated by the p38a downstream target MK2 because activation of MK2 was impaired in the absence of p38a, and direct inhibition of MK2 recapitulated the defects in gene expression observed in p38a-deficient astrocytes. In addition, p38a-deficient MEFs showed reduced expression of Cxcl1 in response to IL-17. In a reciprocal manner, MKP-1-deficient cells overexpressed Cxcl1 in response to IL-17. However, loss of JNK1 and JNK2 did not affect the expression of IL-17-responsive genes. Furthermore, although the pathogenic role of NF-kB signaling in EAE models has been extensively studied (42, 43) , whether it is involved in IL-17R signaling is unknown. Our results therefore indicate a previously unrecognized and selective role of p38a and its negative regulator MKP-1 in mediating IL-17R signaling.
The effector phase of T H 17-mediated EAE is characterized by a persistent inflammatory cascade that can be described by a two-wave hypothesis (44) . After they are primed in the periphery, MOG-specific T H 17 cells infiltrate the CNS, where they reencounter myelin antigens presented by local APCs, including microglia, macrophages, and myeloid DCs (45) . The proinflammatory cytokines released from reactivated T H 17 cells act on CNS-resident cells, such as astrocytes, to produce leukocyte-attracting chemokines, which then mediate a second wave of recruitment of peripheral inflammatory cells. Our results from experiments with the T H 17 transfer model of EAE indicate that p38a activity in CNS-resident cells is intricately involved in amplifying and propagating this inflammatory vicious cycle. Although the initial infiltration of T H 17 cells occurred normally in p38a
NesCre mice, the impaired expression of chemokines and proinflammatory molecules rendered these mice unable to recruit additional T H 17 cells and myeloid cells as EAE progressed. However, loss of p38a in CNS-resident cells did not affect the differentiation of T H 17 or T H 1 cells in the CNS or the periphery. These results suggest that p38a acts in the effector phase of EAE, likely at the transition from wave 1 to wave 2 of the inflammatory cascade.
The precise cellular basis by which IL-17 contributes to EAE pathogenesis remains unresolved. Multiple CNS-resident cells have been implicated in this process, including neurons (46), astrocytes (12), NG2 + glial cells (41) , and possibly microglia (47) . Our in vitro models with astrocytes and MEFs provide some of the earliest genetic evidence for the involvement of the p38a-MKP-1 axis in IL-17R signaling, although the specific types of neuroectoderm-derived cells involved in vivo remain to be established. In addition, p38a likely mediates proinflammatory signals in addition to those stimulated by IL-17, because deficiencies in p38a and MKP-1 also affected, albeit to a lesser extent, gene expression in response to TNF-a. Nevertheless, the crucial role of the p38a-MKP-1 signaling axis in mediating the effector responses of neuroinflammation in vivo makes it a legitimate therapeutic target. Furthermore, inhibition of p38a would be expected to halt the progression of CNS inflammation even when autoreactive T cell responses are under way, which can be explored for therapeutic intervention of MS and possibly other T H 17 cell-mediated inflammatory disorders.
MATERIALS AND METHODS
Mice and bone marrow chimeras C57BL/6, CD45.1, and Nestin-Cre mice were purchased from The Jackson Laboratory. Rosa26-Cre-ER −/− mice were described previously (20, 22, 48, 49) . All mice were backcrossed to the C57BL/6 background for at least eight generations, and mice were used for experiments at 6 to 12 weeks of age. Wild-type littermate controls were in the same genetic background and, where relevant, included Cre + mice to account for the effects of Cre. For complete bone marrow experiments, bone marrow cells from wild-type CD45.1 + mice were transferred into lethally irradiated (11 Gy) 
Induction of EAE
Mice were immunized subcutaneously with 100 ml of emulsified incomplete Freund's adjuvant supplemented with 500 mg of Mycobacterium tuberculosis H37Ra (Difco) and 100 mg of MOG , and received an intraperitoneal injection of 200 ng of pertussis toxin (List Biological Laboratories) at the time of immunization and 48 hours later. The mice were observed daily for clinical signs and scored as described previously (20, 27) . For inducible deletion of floxed alleles in vivo, mice were treated with 2 mg of tamoxifen (Sigma) daily for three continuous days. To induce EAE by adoptive transfer of T H 17-polarized cells, wild-type (C57BL/6 or CD45.1) mice were immunized as described earlier, and after 9 days, DLN cells were isolated and cultured in vitro with MOG peptide and IL-23 for 5 days. Live cells were harvested at the end of the culture period, and 1 × 10 7 to 2 × 10 7 cells were transferred into recipient mice, supplemented by intraperitoneal injection of 200 ng of pertussis toxin on the day of transfer and 48 hours later. Neutralization of IL-17 signaling was performed with a monoclonal antibody (MAB421) specific for IL-17 or an isotype control antibody (MAB006). The mice were injected intraperitoneally with 100 mg of neutralizing antibody or isotype control at days 6, 10, and 14 after immunization.
CNS leukocyte isolation
Sacrificed mice were perfused with phosphate-buffered saline (PBS) containing 2 mM EDTA to remove blood from internal organs. The spinal columns were dissected and cut open, and the intact spinal cord was separated carefully from the vertebrae. The spinal cord was cut into small pieces and placed in digestion solution containing collagenase D (1 mg/ml, Roche) in Hanks' balanced salt solution. Digestion was performed for 45 min at 37°C with brief mixing by vortex every 15 min. At the end of the digestion, the solution was mixed thoroughly and passed through a 40-mm cell strainer. The cells were washed once in PBS, placed in 6 ml of 38% Percoll solution, and centrifuged for 20 min at 860g. Cell pellets were resuspended in buffer or medium for subsequent analysis.
Histopathology and immunohistochemistry
Mice were euthanized, and brains and spinal cords were removed and fixed by immersion with a 10% neutral-buffered formalin solution and decalcified. Fixed tissues were embedded in paraffin, sectioned, and stained with H&E. Serial histological sections were stained immunohistochemically to determine the distribution and types of inflammatory cells in the brain and spinal cord. Spinal cord pathology was assigned scores by an experienced pathologist (P.V.) as described previously (27) .
Cell culture and stimulation
Primary astrocyte cultures were prepared from neonatal mice (2 to 5 days old). In brief, the mice had their cerebral cortices aseptically dissected and the meninges removed. The tissues were then dissociated with 1-ml pipettes, passed through 40-mm cell strainers, and centrifuged. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) and 10% (v/v) fetal bovine serum (FBS) supplemented with penicillin and streptomycin. Primary MEFs were isolated from embryos at day 14.5 of gestation and maintained in DMEM and 10% FBS supplemented with penicillin and streptomycin. The cells were left untreated or were stimulated with IL-17 (200 ng/ml, R&D) or TNF-a (20 ng/ml, R&D) alone or in combination. For treatment with inhibitors, cells were incubated with vehicle or 10 mM MK2 inhibitor (EMD) for 30 min to 1 hour before they were stimulated.
Flow cytometric analysis
To analyze cell surface markers, cells were stained in PBS containing 2% (w/v) bovine serum albumin with anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-TCRb (T cell receptor b) (H57-597), anti-CD11b (M1/70), anti-F4/80 (BM8), anti-CD45 (30-F11), anti-CD45.1 (A20), and anti-CD45. 2 (104) antibodies, all of which were obtained from eBioscience. For intracellular staining, T cells were stimulated for 5 hours with PMA and ionomycin (Sigma) with monensin (BD Biosciences) before they were stained with antibodies specific for IFN-g (XMG1.2) and IL-17 (17B7), both of which were obtained from eBioscience, according to the manufacturer's instructions (BD Biosciences). To detect caspase activity, cells were stained with fluorescein isothiocyanate-conjugated VAD-FMK (Promega) according to the manufacturer's instructions. BrdU and Ki-67 labeling were performed according to the manufacturer's instructions (BD Biosciences). Flow cytometry data were acquired on an upgraded five-color FACScan or LSRII flow cytometers (BD) and were analyzed with FlowJo software (Tree Star).
RNA and protein analyses
Real-time PCR analysis was performed with primer and probe sets obtained from Applied Biosystems, and the abundances of complementary DNAs (cDNAs) of genes of interest were normalized to that of the endogenous control gene Hprt, as described previously (48) . To analyze primary transcripts, RNAs treated with ribonuclease-free deoxyribonuclease I were used for reverse transcription to generate cDNAs. cDNAs were subjected to PCR analysis with the Power SYBR Green Master Mix (Life Technologies) with the following primers: Cxcl1, 5′-GTTAGCTTCTGCCACTTCCAG-3′ (intron 2) and 5′-AGCTTCAGGGTCAAGGCAAG-3′ (exon 3); Cxcl2, 5′-TGAGTGTCTCCCTGGATAGC-3′ (intron 2) and 5′-TTTTGACCGCCCTT-GAGAG-3′ (exon 3); and actin, 5′-CCTTGCATGTCTCAGATCTATC-3′ (intron 3) and 5′-GAGTCCATCACAATGCCTG-3′ (exon 4). To measure mRNA stability, 4-OHT-treated astrocytes from wild-type and p38a
CreER mice were stimulated with TNF-a (10 ng/ml) for 2 hours and then were treated with actinomycin D (5 mg/ml) and IL-17 (50 ng/ml) for the times indicated in the figure legends. For bio-plex assays, the amounts of cytokines in cell culture medium were measured with MILLIPLEX kits (Millipore) for mouse cytokines and chemokines according to the manufacturer's instructions. Western blotting analysis was performed as described previously (50) 
Statistical analysis
P values were calculated with the Mann-Whitney U test (for EAE clinical scores) or the Student's t test (for other analyses). P < 0.05 was considered to be statistically significant, and P values are designated as follows: *P < 0.05; **P < 0.01; ***P < 0.001. All error bars in graphs represent the SEM calculated from at least three replicates.
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